Cite
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
MLA
Delaloge, S., et al. “Effects of Neratinib on Health-Related Quality of Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial.” Annals of Oncology, vol. 30, no. 4, Apr. 2019, pp. 567–74. EBSCOhost, https://doi.org/10.1093/annonc/mdz016.
APA
Delaloge, S., Cella, D., Ye, Y., Buyse, M., Chan, A., Barrios, C. H., Holmes, F. A., Mansi, J., Iwata, H., Ejlertsen, B., Moy, B., Chia, S. K. L., Gnant, M., Smichkoska, S., Ciceniene, A., Martinez, N., Filipović, S., Ben-Baruch, N. E., Joy, A. A., & Langkjer, S. T. (2019). Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Annals of Oncology, 30(4), 567–574. https://doi.org/10.1093/annonc/mdz016
Chicago
Delaloge, S, D Cella, Y Ye, M Buyse, A Chan, C H Barrios, F A Holmes, et al. 2019. “Effects of Neratinib on Health-Related Quality of Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial.” Annals of Oncology 30 (4): 567–74. doi:10.1093/annonc/mdz016.